In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How The UK Is Reinvigorating Its Clinical Trials Industry

Recruitment Has Declined Substantially Since 2017

Executive Summary

In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.

You may also be interested in...



Undertaking Decentralized Clinical Trials In The UK ‘Should Not Be A Luxury’

UK needs to do more to address the current uncertainty among sponsors on how decentralized clinical trials can generate regulatory-grade data.

UK Offers 14-Day Approvals For Lowest-Risk Phase III/IV Trials

The Medicines and Healthcare products Regulatory Agency says it is in “everyone’s best interest” if clinical trial sponsors seeking UK approval for low-risk Phase III and IV studies make use of its new notification scheme that will cut the 30-day statutory evaluation timeline by more than half.

UK Phases In New Standards On Information Materials For Potential Study Participants

The Health Research Authority has developed UK-wide Quality Standards and Design and Review Principles to improve the information given to people who are invited to take part in research. Their use will become mandatory in December.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel